Norbert Vey

List of Publications by Year
in descending order

495 papers	18,270 citations	14655 66 h-index	19749 117 g-index
516 all docs	516 docs citations	516 times ranked	15907 citing authors

#	Article	IF	Citations
1	Mutations of polycombâ€associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. British Journal of Haematology, 2009, 145, 788-800.	2.5	537
2	Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial. Journal of Clinical Oncology, 2004, 22, 4075-4086.	1.6	480
3	Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia. Journal of Clinical Oncology, 2013, 31, 2428-2436.	1.6	462
4	Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia, 2011, 25, 1147-1152.	7.2	430
5	Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure. Journal of Clinical Oncology, 2011, 29, 3322-3327.	1.6	421
6	Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematology,the, 2016, 3, e186-e195.	4.6	359
7	Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood, 2011, 117, 403-411.	1.4	348
8	Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy. Blood, 2016, 128, 253-264.	1.4	320
9	Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood, 2013, 121, 2213-2223.	1.4	313
10	Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood, 2008, 111, 574-582.	1.4	295
11	Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2016, 375, 1044-1053.	27.0	270
12	TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood, 2009, 114, 3285-3291.	1.4	264
13	A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood, 2012, 120, 4317-4323.	1.4	247
14	TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica, 2009, 94, 1676-1681.	3.5	234
15	Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood, 2010, 115, 1690-1696.	1.4	232
16	Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. Journal of Clinical Oncology, 2017, 35, 185-193.	1.6	227
17	Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood, 2012, 119, 3211-3218.	1.4	220
18	ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. British Journal of Haematology, 2010, 151, 365-375.	2.5	199

#	Article	IF	Citations
19	Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. Journal of Clinical Oncology, 2016, 34, 2988-2996.	1.6	190
20	Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood, 2011, 118, 3824-3831.	1.4	187
21	Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood, 2021, 137, 751-762.	1.4	183
22	Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulinâ€“based reduced-intensity preparative regimen. Blood, 2003, 102, 470-476.	1.4	182
23	Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood, 2003, 102, 462-469.	1.4	175
24	BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood, 2013, 122, 3169-3177.	1.4	169
25	International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology, 2014, 32, 1919-1926.	1.6	166
26	Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial. Journal of Clinical Oncology, 2012, 30, 2492-2499.	1.6	165
27	Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood, 2009, 113, 3947-3952.	1.4	158
28	Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer, 2007, 109, 1376-1383.	4.1	150
29	Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer, 2010, 10, 401.	2.6	140
30	Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes and Cancer, 2012, 51, 743-755.	2.8	139
31	Acute leukemia during pregnancy. Cancer, 2005, 104, 110-117.	4.1	136
32	Topotecan and Cytarabine Is an Active Combination Regimen in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Journal of Clinical Oncology, 1999, 17, 2819-2819.	1.6	132
33	Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica, 2008, 93, 1806-1813.	3.5	131
34	Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncology, The, 2015, 16, 1025-1036.	10.7	129
35	Acute Myeloid Leukemia With Translocation (8;21) or Inversion (16) in Elderly Patients Treated With Conventional Chemotherapy: A Collaborative Study of the French CBF-AML Intergroup. Journal of Clinical Oncology, 2009, 27, 4747-4753.	1.6	123
36	<scp>l</scp>â€asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005â€01 randomized trial. British Journal of Haematology, 2011, 153, 58-65.	2.5	118

#	Article	IF	Citations
37	Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood Advances, 2018, 2, 923-932.	5.2	114
38	Activity of the oral mitogenâ€activated protein kinase kinase inhibitor trametinib in <scp>RAS</scp>â€mutant relapsed or refractory myeloid malignancies. Cancer, 2016, 122, 1871-1879.	4.1	113
39	Human VÎ³9VÎ´2 T Cells Specifically Recognize and Kill Acute Myeloid Leukemic Blasts. Journal of Immunology, 2012, 188, 4701-4708.	0.8	112
40	Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia, 2003, 17, 2168-2177.	7.2	111
41	A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D;) Tj ETQq1 1 0.784314 rgBT /Overlo	1.8	110
42	Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1genes. BMC Cancer, 2008, 8, 299.	2.6	109
43	High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. Bone Marrow Transplantation, 2000, 26, 251-255.	2.4	108
44	De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study. Intensive Care Medicine, 2014, 40, 41-49.	8.2	106
45	SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia, 2013, 27, 1401-1403.	7.2	102
46	The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. Leukemia, 2005, 19, 916-920.	7.2	101
47	A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study. Leukemia, 2011, 25, 939-944.	7.2	101
48	Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial. Journal of Clinical Oncology, 2018, 36, 2514-2523.	1.6	99
49	Arsenic Trioxide in Patients With Myelodysplastic Syndromes: A Phase II Multicenter Study. Journal of Clinical Oncology, 2006, 24, 2465-2471.	1.6	95
50	Azacitidine in untreated acute myeloid leukemia: A report on 149 patients. American Journal of Hematology, 2014, 89, 410-416.	4.1	91
51	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 2020, 105, 1507-1516.	3.5	91
52	Haploidentical T Cellâ€“Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigenâ€“Matched Related or Unrelated Donor. Biology of Blood and Marrow Transplantation, 2016, 22, 119-124.	2.0	86
53	The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome. Blood, 2010, 116, 2315-2323.	1.4	79
54	Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. Journal of Clinical Oncology, 2017, 35, 1591-1597.	1.6	79

#	Article	IF	Citations
55	Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study. Blood, 2011, 118, 79-79.	1.4	77
56	Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Blood, 2005, 106, 4407-4411.	1.4	76
57	Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, in Patients Age 60 Years or Older With Previously Untreated Acute Myeloid Leukemia. Journal of Clinical Oncology, 2007, 26, 25-31.	1.6	75
58	Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity. Frontiers in Immunology, 2014, 5, 122.	4.8	75
59	Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia. Oncotarget, 2016, 7, 32532-32542.	1.8	75
60	Current status of reduced intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica, 2007, 92, 533-541.	3.5	74
61	The increase from 2.5 to 5â€‰mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone Marrow Transplantation, 2012, 47, 639-645.	2.4	73
62	Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia. Blood, 2011, 117, 6650-6659.	1.4	72
63	Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1. Leukemia, 2012, 26, 662-674.	7.2	72
64	How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?. Blood Advances, 2019, 3, 4238-4251.	5.2	72
65	Single-Agent Laromustine, A Novel Alkylating Agent, Has Significant Activity in Older Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 815-821.	1.6	70
66	Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes. Oncotarget, 2015, 6, 8388-8396.	1.8	69
67	Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities. Blood, 2011, 118, 679-685.	1.4	68
68	Acute myeloid leukemia patients clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts. Haematologica, 2016, 101, e185-e188.	3.5	68
69	Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. International Journal of Antimicrobial Agents, 2008, 31, 135-141.	2.5	67
70	Acute myeloid leukemia with myelodysplasiaâ€related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations. American Journal of Hematology, 2012, 87, 659-662.	4.1	67
71	Features of large granular lymphocytes (LGL) expansion following allogeneic stem cell transplantation: a long-term analysis. Leukemia, 2002, 16, 2129-2133.	7.2	66
72	Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. European Journal of Haematology, 2013, 90, 355-364.	2.2	66

#	Article	IF	Citations
73	Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents. Leukemia, 2013, 27, 1283-1290.	7.2	65
74	Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). Blood, 2019, 134, 570-570.	1.4	64
75	Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study. Blood, 2005, 105, 3072-3078.	1.4	63
76	Azacitidine for the treatment of relapsed and refractory AML in older patients. Leukemia Research, 2015, 39, 124-130.	0.8	63
77	Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graftâ€versusâ€host disease in reducedâ€intensity conditioning transplantation for hematologic diseases. Cancer, 2013, 119, 986-992.	4.1	62
78	Targeting apoptosis in acute myeloid leukaemia. British Journal of Cancer, 2017, 117, 1089-1098.	6.4	61
79	The benefit of induction chemotherapy in patients age ? 75 years. Cancer, 2004, 101, 325-331.	4.1	60
80	Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: A retrospective analysis on 112 patients. Leukemia Research, 2010, 34, 1430-1436.	0.8	60
81	Early Allogeneic Stem-Cell Transplantation for Young Adults With Acute Myeloblastic Leukemia in First Complete Remission: An Intent-to-Treat Long-Term Analysis of the BGMT Experience. Journal of Clinical Oncology, 2005, 23, 7676-7684.	1.6	59
82	Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. Blood, 2004, 103, 4666-4668.	1.4	58
83	Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. Haematologica, 2017, 102, 373-380.	3.5	58
84	Therapeutic Targeting of c-Myc in T-Cell Acute Lymphoblastic Leukemia (T-ALL). Oncotarget, 2014, 5, 3168-3172.	1.8	58
85	Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.. Journal of Clinical Oncology, 1997, 15, 1722-1729.	1.6	56
86	Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer, 2005, 104, 1931-1938.	4.1	56
87	Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. Blood Advances, 2021, 5, 176-184.	5.2	56
88	Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. Journal of Experimental Medicine, 2021, 218, .	8.5	56
89	A randomized phase II trial of azacitidine +/- epoetin-Â in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents. Haematologica, 2016, 101, 918-925.	3.5	55
90	Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts). Blood, 2014, 124, 116-116.	1.4	55

#	Article	IF	Citations
91	Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study. Blood, 2020, 136, 1-2.	1.4	54
92	Critically ill allogenic HSCT patients in the intensive care unit: a systematic review and meta-analysis of prognostic factors of mortality. Bone Marrow Transplantation, 2018, 53, 1233-1241.	2.4	53
93	MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine Â± idasanutlin in relapsed or refractory acute myeloid leukemia. Future Oncology, 2020, 16, 807-815.	2.4	53
94	Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood, 2009, 114, 4027-4033.	1.4	52
95	Risk factors of Ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patients. Clinical Microbiology and Infection, 2014, 20, 160-166.	6.0	52
96	Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients. Leukemia, 2014, 28, 2422-2424.	7.2	52
97	Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a â€˜donorâ€™ versus â€˜no donorâ€™ comparison. Leukemia, 2009, 23, 194-196.	7.2	51
98	Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: Results from the GET-LALA group. Leukemia Research, 2008, 32, 1741-1750.	0.8	50
99	Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study. Blood, 2011, 118, 5099-5107.	1.4	50
100	The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience. Blood, 2012, 120, 5084-5085.	1.4	50
101	A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse. Leukemia, 2013, 27, 1479-1486.	7.2	50
102	Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction. Leukemia Research, 2015, 39, 296-306.	0.8	50
103	A Phase II Study of Interleukin-2 in 49 Patients with Relapsed or Refractory Acute Leukemia. Leukemia and Lymphoma, 1998, 31, 343-349.	1.3	49
104	High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplantation, 2007, 39, 301-306.	2.4	49
105	Outcome of Acute Promyelocytic Leukemia (APL) in Children and Adolescents: An Analysis in Two Consecutive Trials of the European APL Group. Journal of Clinical Oncology, 2012, 30, 1641-1646.	1.6	49
106	Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure. British Journal of Haematology, 2012, 157, 764-766.	2.5	49
107	Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms. American Journal of Hematology, 2018, 93, 330-338.	4.1	49
108	Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia. Frontiers in Immunology, 2017, 8, 573.	4.8	47

#	Article	IF	Citations
109	Autologous Transplantation of Blood Stern Cells Mobilized with Filgrastim Alone in 93 Patients with Malignancies: The Number of CD34+ Cells Reinfused Is the Only Factor Predicting Both Granulocyte and Platelet Recovery. Stem Cells and Development, 1996, 5, 663-670.	1.0	46
110	Alteration of cohesin genes in myeloid diseases. American Journal of Hematology, 2010, 85, 717-719.	4.1	46
111	BTN3A molecules considerably improve Vî³9Vî´2T cells-based immunotherapy in acute myeloid leukemia. OncoImmunology, 2016, 5, e1146843.	4.6	46
112	Natural killer and Î³Î´ T cells in haematological malignancies: enhancing the immune effectors. Trends in Molecular Medicine, 2009, 15, 275-284.	6.7	45
113	Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): A report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM). Leukemia Research, 2013, 37, 637-640.	0.8	45
114	Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Expert Opinion on Investigational Drugs, 2016, 25, 307-317.	4.1	45
115	Low blood dendritic cells in chronic myeloid leukaemia patients correlates with loss of CD34+ /CD38- primitive haematopoietic progenitors. British Journal of Haematology, 2002, 119, 115-118.	2.5	44
116	Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling. Oncogene, 2004, 23, 9381-9391.	5.9	44
117	Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: A report on 62 cases. Leukemia Research, 2011, 35, 863-867.	0.8	44
118	Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group. Haematologica, 2014, 99, 46-53.	3.5	44
119	BTN2A1, an immune checkpoint targeting Vî³9Vî´2 T cell cytotoxicity against malignant cells. Cell Reports, 2021, 36, 109359.	6.4	44
120	Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia. Leukemia and Lymphoma, 2013, 54, 1228-1234.	1.3	43
121	Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials. Leukemia, 2006, 20, 336-344.	7.2	42
122	Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs. Bone Marrow Transplantation, 2012, 47, 549-555.	2.4	42
123	Genomic analysis of myeloproliferative neoplasms in chronic and acute phases. Haematologica, 2017, 102, e11-e14.	3.5	42
124	Antithymocyte Globulin in Reduced-Intensity Conditioning Regimen Allows a High Disease-Free Survival Exempt of Long-Term Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2014, 20, 370-374.	2.0	40
125	HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison. Biology of Blood and Marrow Transplantation, 2018, 24, 1449-1454.	2.0	39
126	Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase. Haematologica, 2014, 99, 37-45.	3.5	38

#	Article	IF	Citations
127	Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies. Haematologica, 2012, 97, 213-218.	3.5	37
128	Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. Journal of Clinical Oncology, 2017, 35, 1223-1230.	1.6	37
129	NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML. OncoImmunology, 2017, 6, e1307491.	4.6	37
130	CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Experimental Hematology, 2004, 32, 1097-1102.	0.4	36
131	Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies. Experimental Hematology, 2010, 38, 1241-1250.	0.4	36
132	Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletionâ€"The GFM experience. Leukemia Research, 2011, 35, 1444-1448.	0.8	36
133	Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms. Blood Cancer Journal, 2011, 1, e33-e33.	6.2	36
134	PICALMâ€"MLLT10 acute myeloid leukemia: A French cohort of 18 patients. Leukemia Research, 2012, 36, 1365-1369.	0.8	36
135	Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia. American Journal of Hematology, 2014, 89, 604-609.	4.1	36
136	Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML, an ALFA study. Blood, 2021, 137, 2827-2837.	1.4	36
137	A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia. Leukemia Research, 2010, 34, 254-257.	0.8	35
138	Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. Expert Opinion on Investigational Drugs, 2011, 20, 287-295.	4.1	35
139	Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine. Leukemia, 2011, 25, 1207-1209.	7.2	35
140	Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT. Bone Marrow Transplantation, 2011, 46, 1000-1005.	2.4	35
141	Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies. Haematologica, 2014, 99, 1762-1768.	3.5	35
142	Kinetics of Cytotoxic Lymphocytes Reconstitution after Induction Chemotherapy in Elderly AML Patients Reveals Progressive Recovery of Normal Phenotypic and Functional Features in NK Cells. Frontiers in Immunology, 2017, 8, 64.	4.8	35
143	Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplantation, 2004, 34, 527-530.	2.4	34
144	NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia. Oncotarget, 2017, 8, 49548-49563.	1.8	34

#	Article	IF	Citations
145	Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results. Haematologica, 2007, 92, 1327-1334.	3.5	33
146	A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia. Blood, 2021, 137, 524-532.	1.4	33
147	Lenalidomide in lowerâ€risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesisâ€stimulating agents. British Journal of Haematology, 2012, 156, 619-625.	2.5	32
148	A phase I firstâ€inâ€human study with tefinostat â€“ a monocyte/macrophage targeted histone deacetylase inhibitor â€“ in patients with advanced haematological malignancies. British Journal of Haematology, 2013, 162, 191-201.	2.5	32
149	Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial. Journal of Clinical Oncology, 2018, 36, 3203-3210.	1.6	32
150	Phase 1 Cohort Expansion of Flotetuzumab, a CD123Ã—CD3 Bispecific DartÂ® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood, 2018, 132, 764-764.	1.4	32
151	Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study. Investigational New Drugs, 1999, 17, 89-95.	2.6	31
152	Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica, 2014, 99, 1380-1386.	3.5	31
153	Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies. Cancer, 2015, 121, 1809-1816.	4.1	31
154	Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing. Leukemia, 2016, 30, 966-970.	7.2	31
155	Longâ€term followâ€up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients. American Journal of Hematology, 2013, 88, 556-559.	4.1	30
156	Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy. Blood, 2019, 134, 229-229.	1.4	30
157	Second Neoplasms Following High-dose Chemotherapy and Autologous Stem Cell Transplantation for Malignant Lymphomas: A Report of Six Cases in a Cohort of 171 Patients from a Single Institution. Leukemia and Lymphoma, 1998, 31, 187-194.	1.3	29
158	Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin. Leukemia, 2010, 24, 467-469.	7.2	29
159	Consent for Biobanking: Assessing the Understanding and Views of Cancer Patients. Journal of the National Cancer Institute, 2011, 103, 154-157.	6.3	29
160	Adherence to Leukemia Maintenance Therapy: A Comparative Study Among Children, Adolescents, and Adults. Pediatric Hematology and Oncology, 2012, 29, 428-439.	0.8	29
161	Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure. Haematologica, 2013, 98, e18-e19.	3.5	29
162	Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b studyâ‹†. Leukemia Research, 2021, 100, 106489.	0.8	29

#	Article	IF	Citations
163	High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	29
164	A Phase II Study of Postâ€“Remission Therapy with Azacitidine (AZA) in Patients with AML Post-MDS and High-Risk MDS: A GFM Group Study.. Blood, 2009, 114, 844-844.	1.4	29
165	Addition of Rituximab Improves the Outcome of Adult Patients with CD20-Positive, Ph-Negative, B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Graall-R 2005 Study. Blood, 2015, 126, 1-1.	1.4	29
166	Clofarabine for the treatment of adult acute lymphoid leukemia: the Group for Research on Adult Acute Lymphoblastic Leukemia intergroup. Leukemia and Lymphoma, 2015, 56, 847-857.	1.3	28
167	Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia. Haematologica, 2014, 99, e185-e187.	3.5	27
168	A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia. Blood, 2014, 124, 117-117.	1.4	27
169	Elacytarabine has singleâ€agent activity in patients â€¨with advanced acute myeloid leukaemia. British Journal of Haematology, 2012, 158, 581-588.	2.5	26
170	Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia. Blood Advances, 2018, 2, 2063-2071.	5.2	26
171	Correction of aplastic anaemia complicating paroxysmal nocturnal haemoglobinuria: absence of eradication of the PNH clone and dependence of response on cyclosporin A administration. British Journal of Haematology, 1996, 93, 42-44.	2.5	25
172	Lymphomatoid papulosis associated with both severe hypereosinophilic syndrome and CD30 positive large T-cell lymphoma. Cancer, 2000, 89, 2138-2143.	4.1	25
173	Concomitant germâ€line <scp>RUNX</scp>1 and acquired <scp>ASXL</scp>1 mutations in a Tâ€cell acute lymphoblastic leukemia. European Journal of Haematology, 2013, 91, 277-279.	2.2	25
174	A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor. American Journal of Hematology, 2014, 89, 83-87.	4.1	25
175	Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities. Frontiers in Immunology, 2018, 9, 977.	4.8	25
176	A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia. Leukemia Research, 2006, 30, 1591-1595.	0.8	24
177	Common features of myeloproliferative disorders with t(8;9)(p12;q33) and CEP110â€“FGFR1 fusion: Report of a new case and review of the literature. Leukemia Research, 2008, 32, 1304-1308.	0.8	24
178	Monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factor. Critical Care, 2008, 12, R17.	5.8	24
179	Impact of Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation on Women's Fertility. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 704-710.	0.4	24
180	Increased NK Cell Maturation in Patients with Acute Myeloid Leukemia. Frontiers in Immunology, 2015, 6, 564.	4.8	24

#	Article	IF	Citations
181	Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients. Cancer Research, 2016, 76, 2082-2086.	0.9	24
182	Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group. Haematologica, 2018, 103, 2033-2039.	3.5	24
183	Autoimmune diseases in myelodysplastic syndrome favors patients survival: A case control study and literature review. Autoimmunity Reviews, 2019, 18, 36-42.	5.8	24
184	Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remission. Bone Marrow Transplantation, 2006, 37, 709-710.	2.4	23
185	A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. Annals of Oncology, 2012, 23, 2687-2695.	1.2	23
186	The patientâ€™s CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide. Bone Marrow Transplantation, 2016, 51, 1134-1136.	2.4	23
187	Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML. Bone Marrow Transplantation, 2017, 52, 620-621.	2.4	23
188	JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid Leukemia. Cancer Research, 2017, 77, 6627-6640.	0.9	23
189	Rescue of haemopoiesis by a combination of growth factors including stem-cell factor. Lancet, The, 2000, 356, 1325-1326.	13.7	22
190	Simultaneous Occurrence of Kaposi's Sarcoma and Chronic Myelogenous Leukemia. Leukemia and Lymphoma, 2001, 41, 425-428.	1.3	22
191	Costâ€“effectiveness of repeated aphereses in poor mobilizers undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation. Leukemia, 2003, 17, 811-813.	7.2	22
192	Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALAâ€87 and LALAâ€94 trials. Cancer, 2007, 110, 2747-2755.	4.1	22
193	T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes. Bone Marrow Transplantation, 2016, 51, 194-198.	2.4	22
194	Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des MyÃ©lodysplasies. Haematologica, 2017, 102, 728-735.	3.5	22
195	Nelarabine for T Cell Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: An Opportunity to Improve Survival. Biology of Blood and Marrow Transplantation, 2013, 19, 1124-1126.	2.0	21
196	Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia. Leukemia, 2014, 28, 440-443.	7.2	21
197	Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia. Blood Cancer Journal, 2015, 5, e292-e292.	6.2	21
198	Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study. Blood, 2018, 132, 767-767.	1.4	21

#	Article	IF	Citations
199	A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL).. Journal of Clinical Oncology, 2015, 33, 3065-3065.	1.6	21
200	Bone marrow as stem cell source for allogeneic HLA-identical sibling transplantation following reduced-intensity preparative regimen. Experimental Hematology, 2003, 31, 873-880.	0.4	20
201	Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3â€ITD molecular status for cytogenetically normal AML patients: A GOELAMS study. American Journal of Hematology, 2012, 87, 1052-1056.	4.1	20
202	Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cellâ€“Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients. Biology of Blood and Marrow Transplantation, 2019, 25, 1803-1809.	2.0	20
203	Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients. Bone Marrow Transplantation, 2019, 54, 1067-1076.	2.4	20
204	Outcome of older (â‰¥70 years) APL patients frontline treated with or without arsenic trioxideâ€”an International Collaborative Study. Leukemia, 2020, 34, 2333-2341.	7.2	20
205	Treatment of Lower Risk MDS with Del 5q with Lenalidomide (LEN): Results of the French ATU Program.. Blood, 2009, 114, 2764-2764.	1.4	20
206	Improved outcome of patients with lowâ€•and intermediateâ€risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine. Cancer, 2011, 117, 974-981.	4.1	19
207	Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome â€“ Emphasis on optimized dosing schedules and new formulations. Leukemia Research, 2015, 39, 1028-1033.	0.8	19
208	Comparison of 60 or 90 mg/m² of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics. American Journal of Hematology, 2015, 90, E29-30.	4.1	19
209	Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients. Bone Marrow Transplantation, 2019, 54, 1730-1737.	2.4	19
210	Diagnosis and treatment of therapy-related acute myeloid leukemia. Critical Reviews in Oncology/Hematology, 2022, 171, 103607.	4.4	19
211	Effect of Complete Remission on Survival in Patients With Acute Myelogenous Leukemia Receiving First Salvage Therapy. Blood, 1999, 93, 3149-3150.	1.4	18
212	Phase I and pharmacokinetic study of elacytarabine, a novel 5â€²-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies. Leukemia, 2012, 26, 1686-1689.	7.2	18
213	Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 349-355.	2.4	18
214	A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study. Blood Cancer Journal, 2020, 10, 64.	6.2	18
215	Low-intensity regimens versus standard-intensity induction strategies in acute myeloid leukemia. Therapeutic Advances in Hematology, 2020, 11, 204062072091301.	2.5	18
216	Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes. Blood Cancer Journal, 2011, 1, e18-e18.	6.2	17

#	Article	IF	Citations
217	Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?. Leukemia Research, 2012, 36, 397-400.	0.8	17
218	Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT. Bone Marrow Transplantation, 2013, 48, 1472-1477.	2.4	17
219	Question prompt list responds to information needs of myelodysplastic syndromes patients and caregivers. Leukemia Research, 2015, 39, 599-605.	0.8	17
220	Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities. American Journal of Hematology, 2015, 90, 859-863.	4.1	17
221	Evaluation of the Incidence of Hematologic Malignant Neoplasms Among Breast Cancer Survivors in France. JAMA Network Open, 2019, 2, e187147.	5.9	17
222	Targeted molecular characterization shows differences between primary and secondary myelofibrosis. Genes Chromosomes and Cancer, 2020, 59, 30-39.	2.8	17
223	Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. Haematologica, 2021, 106, 1414-1422.	3.5	17
224	Phase 1b Study Of The MDM2 Antagonist RG7112 In Combination With 2 Doses/Schedules Of Cytarabine. Blood, 2013, 122, 498-498.	1.4	17
225	Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients. Cancers, 2022, 14, 2025.	3.7	17
226	Large granular lymphocytes (LGL) following non-myeloablative allogeneic bone marrow transplantation: a case report. Bone Marrow Transplantation, 2001, 28, 1157-1160.	2.4	16
227	Platelet recovery and transfusion needs after reduced intensity conditioning allogeneic peripheral blood stem cell transplantation. Experimental Hematology, 2010, 38, 55-60.	0.4	16
228	Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS. Leukemia Research, 2011, 35, 1530-1533.	0.8	16
229	Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes. Leukemia Research, 2014, 38, 29-33.	0.8	16
230	Prognostic significance of myelodysplasiaâ€related changes according to the <scp>WHO</scp> classification among <scp>ELN</scp>â€intermediateâ€risk <scp>AML</scp> patients. American Journal of Hematology, 2015, 90, E22-4.	4.1	16
231	Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blastâ€phase myeloproliferative neoplasms. British Journal of Haematology, 2016, 172, 628-630.	2.5	16
232	A Pilot Study of Autologous Bone Marrow Transplantation Followed by Recombinant Interleukin-2 in Malignant Lymphomas. Leukemia and Lymphoma, 1996, 21, 107-114.	1.3	15
233	Early administration of recombinant erythropoietin improves hemoglobin recovery after reduced intensity conditioned allogeneic stem cell transplantation. Bone Marrow Transplantation, 2005, 36, 901-906.	2.4	15
234	Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights. Annals of Oncology, 2021, 32, 1046-1048.	1.2	15

#	Article	IF	Citations
235	Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy. Oncotarget, 2017, 8, 81926-81935.	1.8	15
236	CD34+ immunoselected cells for poor graft function following allogeneic BMT. Cytotherapy, 2000, 2, 367-370.	0.7	14
237	Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia. Leukemia and Lymphoma, 2017, 58, 1880-1886.	1.3	14
238	Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents. Blood Cancer Journal, 2017, 7, e562-e562.	6.2	14
239	In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study. Blood Advances, 2022, 6, 1804-1812.	5.2	14
240	Flotetuzumab, an Investigational CD123 x CD3 Bispecific DartÂ® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients. Blood, 2019, 134, 733-733.	1.4	14
241	Bortezomib combined with lowâ€dose cytarabine in Intermediateâ€2 and high risk myelodysplastic syndromes. A phase <scp>I</scp>/<scp>II</scp> Study by the <scp>GFM</scp>. British Journal of Haematology, 2012, 158, 232-237.	2.5	13
242	Targeting Age-Related Changes in the Biology of Acute Myeloid Leukemia: Is the Patient Seeing the Progress?. Interdisciplinary Topics in Gerontology, 2013, 38, 73-84.	3.6	13
243	Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system. Haematologica, 2016, 101, e427-e428.	3.5	13
244	Risk of Hematologic Malignant Neoplasms after Postoperative Treatment of Breast Cancer. Cancers, 2019, 11, 1463.	3.7	13
245	Azacytidine (AZA) as First Line Therapy in AML: Results of the French ATU Program.. Blood, 2009, 114, 843-843.	1.4	13
246	The Upper Age Limit for a Pediatric-Inspired Therapy in Younger Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL)? Analysis of the Graall-2005 Study. Blood, 2016, 128, 762-762.	1.4	13
247	Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial. Blood Advances, 2022, , .	5.2	13
248	Re: Familial Multiple Myeloma: a Family Study and Review of the Literature. Journal of the National Cancer Institute, 2002, 94, 461-462.	6.3	12
249	Autologous stem cell transplantation for acute myelogenous leukemia in first complete remission: a 6-year follow-up study of 101 patients from a single institution. Bone Marrow Transplantation, 2004, 33, 177-182.	2.4	12
250	One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission. British Journal of Haematology, 2005, 129, 403-410.	2.5	12
251	Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level. Annals of Hematology, 2012, 91, 39-46.	1.8	12
252	Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. Leukemia and Lymphoma, 2013, 54, 1538-1540.	1.3	12

#	Article	IF	Citations
253	5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies. European Journal of Cancer, 2014, 50, 196.	2.8	12
254	Prognostic impact of early adjunctive corticosteroid therapy in non-HIV oncology or haematology patients with Pneumocystis jirovecii pneumonia: A propensity score analysis. PLoS ONE, 2021, 16, e0250611.	2.5	12
255	Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia. Blood, 2020, 136, 16-18.	1.4	12
256	Towards a Pediatric Approach in Adults with Acute Lymphoblastic Leukemia (ALL): The GRAALL-2003 Study.. Blood, 2006, 108, 147-147.	1.4	12
257	RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia. Leukemia, 2022, 36, 1237-1252.	7.2	12
258	A randomised phase <scp>II</scp> study of azacitidine (<scp>AZA</scp>) alone or with Lenalidomide (<scp>LEN</scp>), Valproic acid (<scp>VPA</scp>) or Idarubicin (<scp>IDA</scp>) in <scp>higherâ€Risk MDS</scp> or low blast <scp>AML</scp>: <scp>GFM</scp>'s â€œpick a winnerâ€•trial, with the impact of somatic mutations. British Journal of Haematology, 2022, 198, 535-544.	2.5	12
259	Myelodysplastic features developing in Philadephia-negative cells during imatinib mesylate therapy for CML: report of a new case. Leukemia, 2003, 17, 1901-1902.	7.2	11
260	Arsenic trioxide for the treatment of myelodysplastic syndromes. Expert Opinion on Pharmacotherapy, 2004, 5, 613-621.	1.8	11
261	Immunotherapy of acute myeloid leukemia based on Î³Î´ T cells. OncoImmunology, 2012, 1, 1614-1616.	4.6	11
262	A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course. Leukemia and Lymphoma, 2014, 55, 2114-2119.	1.3	11
263	Poor Outcome with Nonmyeloablative Conditioning Regimen before Cord Blood Transplantation for Patients with High-Risk Acute Myeloid Leukemia Compared with Matched Related orÂUnrelated Donor Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1560-1565.	2.0	11
264	Azacitidine improves outcome in higherâ€risk <scp>MDS</scp> patients with chromosome 7 abnormalities: a retrospective comparison of <scp>GESMD</scp> and <scp>GFM</scp> registries. British Journal of Haematology, 2018, 181, 350-359.	2.5	11
265	Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation. Clinical Epigenetics, 2019, 11, 141.	4.1	11
266	Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005). Blood, 2014, 124, 409-409.	1.4	11
267	Early Allogeneic Bone Marrow Transplantation for Young Adults with Acute Myeloid Leukemia in First Complete Remission: The 17 Year Experience of the BGMT Group.. Blood, 2004, 104, 619-619.	1.4	11
268	Donor CD3+ lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: Single-center experience. Experimental Hematology, 2013, 41, 17-27.	0.4	10
269	Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification. Blood Cancer Journal, 2017, 7, e594-e594.	6.2	10
270	Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase <scp>II</scp> addâ€on study from the Groupe Francophone des Myelodysplasies. British Journal of Haematology, 2018, 180, 735-737.	2.5	10

#	Article	IF	Citations
271	Risk of secondary hematologic malignancies associated with breast cancer chemotherapy and Gâ€CSF support: A nationwide populationâ€based cohort. International Journal of Cancer, 2021, 148, 375-384.	5.1	10
272	Is AraC Required In the Treatment of Standard Risk APL? Long Term Results of a Randomized Trial (APL) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.4	10
273	Presence of TET2 Mutation Predicts A Higher Response Rate to Azacitidine In MDS and AML Post MDS. Blood, 2010, 116, 439-439.	1.4	10
274	Dose-Intensity Impacts On Survival of Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated in Adult Departments by a Pediatric Protocol (FRALLE 2000BT). Blood, 2012, 120, 3561-3561.	1.4	10
275	Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy. Oncotarget, 2017, 8, 37866-37874.	1.8	10
276	Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance. Cancers, 2021, 13, 5608.	3.7	10
277	Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins. Blood Cancer Journal, 2022, 12, 14.	6.2	10
278	Treatment of Chronic Myelogenous Leukemia with Interleukin-2: A Phase II Study in 21 Patients. Journal of Immunotherapy, 1999, 22, 175-181.	2.4	9
279	Presence of a minor Philadelphia-positive clone in young adults withde novoT-cell ALL. Leukemia and Lymphoma, 2009, 50, 485-487.	1.3	9
280	Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts. Haematologica, 2013, 98, 576-583.	3.5	9
281	Association between health literacy, communication and psychological distress among myelodysplastic syndromes patients. Leukemia Research, 2018, 73, 44-50.	0.8	9
282	Phase 3 results for vosaroxin/cytarabine in the subset of patients â‰¥60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica, 2018, 103, e514-e518.	3.5	9
283	Myelodysplastic Syndromes: How to Recognize Risk and Avoid Acute Myeloid Leukemia Transformation. Current Oncology Reports, 2020, 22, 4.	4.0	9
284	A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm's 'pick a Winner' Trial. Blood, 2018, 132, 467-467.	1.4	9
285	Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific DartÂ® Molecule for T-Cell Redirected Therapy. Blood, 2018, 132, 2738-2738.	1.4	9
286	Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies. Oncotarget, 2016, 7, 85937-85947.	1.8	9
287	Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusion. International Journal of Oncology, 2005, 26, 1485.	3.3	8
288	Reduced-intensity conditioning allogeneic stem cell transplantation for patients with chemoresistant or relapsed follicular lymphoma. British Journal of Haematology, 2006, 135, 408-410.	2.5	8

#	Article	IF	Citations
289	Cloretazine for the treatment of acute myeloid leukemia. Expert Review of Anticancer Therapy, 2006, 6, 321-328.	2.4	8
290	Outcome after reduced-intensity conditioning allogeneic SCT for AML in first complete remission: comparison of two regimens. Bone Marrow Transplantation, 2008, 42, 689-691.	2.4	8
291	Contributing to research via biobanks: what it means to cancer patients. Health Expectations, 2014, 17, 523-533.	2.6	8
292	PcG methylation of the HIST1 cluster defines an epigenetic marker of acute myeloid leukemia. Leukemia, 2015, 29, 1202-1206.	7.2	8
293	Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 241-242.	0.4	8
294	Clinical outcome of FLAG-IDA chemotherapy sequential with Fluâ€“Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes. Bone Marrow Transplantation, 2019, 54, 458-464.	2.4	8
295	Socioeconomic deprivation is associated with decreased survival in patients with acute myeloid leukemia. Cancer Epidemiology, 2020, 66, 101699.	1.9	8
296	Phase 2 Trial of Single Agent Gedatolisib (PF-05212384), a Dual PI3K/mTOR Inhibitor, for Adverse Prognosis and Relapse/Refractory AML: Clinical and Transcriptomic Results. Blood, 2018, 132, 5233-5233.	1.4	8
297	Low-Dose Clofarabine Has Significant Activity in High-Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia Post-MDS (sAML) After Azacitidine (AZA) Failure: Interim Results of the GFM Clo08 Dose Escalating Phase I/II Study (NCT0106325). Blood, 2011, 118, 609-609.	1.4	8
298	Massive ascites of donor T-cell origin in a patient with acute GVHD after a reduced-intensity allograft for CLL. Bone Marrow Transplantation, 2003, 32, 961-963.	2.4	7
299	Gain of CBL-interacting protein, a possible alternative to CBL mutations in myeloid malignancies. Leukemia, 2010, 24, 1539-1541.	7.2	7
300	Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction. Leukemia and Lymphoma, 2012, 53, 2186-2191.	1.3	7
301	Evaluation of comorbidity indexes in the outcome of elderly patients treated for acute lymphoblastic leukemia. Leukemia and Lymphoma, 2014, 55, 2211-2212.	1.3	7
302	T-cell-replete haploidentical transplantation in acute myeloid leukemia. Experimental Hematology, 2018, 58, 5-16.	0.4	7
303	Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) In AML and Higher Risk MDS with Del 5q. Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies (GFM). Blood, 2010, 116, 508-508.	1.4	7
304	Repeated Dosing Of Anti-KIR (IPH2101) As Maintenance Therapy In Ederly Patients With Acute Myeloid Leukemia. Blood, 2013, 122, 2696-2696.	1.4	7
305	A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies. Blood, 2014, 124, 4417-4417.	1.4	7
306	A phase I, first-in-human study of MGD006/S80880 (CD123 x CD3 DART) in AML/MDS.. Journal of Clinical Oncology, 2017, 35, TPS7070-TPS7070.	1.6	7

#	Article	IF	Citations
307	Long Term Infectious Complications Following Reduced Intensity Conditioning (RIC) Allogeneic HLA-Identical Sibling Transplantation (allo-SCT).. Blood, 2006, 108, 2850-2850.	1.4	7
308	Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose. Blood, 2020, 136, 40-42.	1.4	7
309	Large B-cell lymphomas in adolescents and young adults in comparison to adult patients: a matched-control analysis in 55 patients. Leukemia and Lymphoma, 2014, 55, 1849-1853.	1.3	6
310	COMPARISON OF THREE DISTINCT PROPHYLACTIC AGENTS AGAINST INVASIVE FUNGAL INFECTIONS IN PATIENTS UNDERGOING HAPLO-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION AND POST-TRANSPLANT CYCLOPHOSPHAMIDE. Mediterranean Journal of Hematology and Infectious Diseases, 2015, 7, e2015048.	1.3	6
311	Impact of bodyâ€surface area on patientsâ€™ outcome in younger adults with acute myeloid leukemia. European Journal of Haematology, 2017, 98, 443-449.	2.2	6
312	Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. Biology of Blood and Marrow Transplantation, 2018, 24, 1754-1758.	2.0	6
313	Fit Î±Î² T-cell receptor suppresses leukemogenesis of Pten-deficient thymocytes. Haematologica, 2018, 103, 999-1007.	3.5	6
314	Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome. Annals of Hematology, 2020, 99, 773-780.	1.8	6
315	Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/â^' Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone. Blood, 2010, 116, 1880-1880.	1.4	6
316	Comparison Of Umbilical Cord Blood and Haploidentical Donor Grafts In Adults With High Risk Hematologic Diseases After Fludarabine Cyclophosphamide and TBI 2 Gy Based Reduced-Intensity Conditioning Regimen Stem Cell Transplantation. Blood, 2013, 122, 3288-3288.	1.4	6
317	Durable Overall Survival Benefit in Patients â‰¥ 60 Years with Relapsed or Refractory AML Treated with Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial. Blood, 2016, 128, 903-903.	1.4	6
318	Transient detection of Î²-galactosidase activity in hematopoietic cells, following reinjection of retrovirally marked autologous blood progenitors in patients with breast or ovarian cancer receiving high-dose chemotherapy. Experimental Hematology, 2002, 30, 108-115.	0.4	5
319	Sometimes appendicitis can wait. American Journal of Hematology, 2004, 76, 312-313.	4.1	5
320	Early allogeneic stem cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: An intent-to-treat analysis of the long-term experience of the BGMT group. Biology of Blood and Marrow Transplantation, 2005, 11, 17-18.	2.0	5
321	Early preemptive ICU admission for newly diagnosed high-risk acute myeloid leukemia patients. Leukemia Research, 2018, 68, 29-31.	0.8	5
322	Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial. Leukemia and Lymphoma, 2018, 59, 2135-2143.	1.3	5
323	Acute erythroid leukemias have a distinct molecular hierarchy from non-erythroid acute myeloid leukemias. Haematologica, 2020, 105, e340-e342.	3.5	5
324	Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study. Leukemia, 2021, 35, 1291-1300.	7.2	5

#	Article	IF	Citations
325	Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML. Blood, 2019, 134, 1416-1416.	1.4	5
326	Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab. Blood, 2020, 136, 19-21.	1.4	5
327	Rituximab Given after High Dose Therapy and Autologous Stem Cell Transplantation Induces Durable Clearance of Minimal Residual Disease in about Half of the Patients with Follicular Non Hodgkinâ€™s Lymphoma : 36 Months Results of a Multicenter Open Label Phase II Trial (M39012 Trial).. Blood, 2004, 104, 747-747.	1.4	5
328	Azacytidine in Refractory or Relapsed AML After Intensive Chemotherapy (IC): Results of the French ATU Program.. Blood, 2009, 114, 1054-1054.	1.4	5
329	Updated Clinical Activity of Graspa Versus Native l-Asparaginase in Combination with Cooprall Regimen in Phase 3 Randomized Trial in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517). Blood, 2015, 126, 3723-3723.	1.4	5
330	The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort. Blood, 2016, 128, 1063-1063.	1.4	5
331	In Vitro Screening of a 1280 FDA-Approved Drugs Library against Multidrug-Resistant and Extensively Drug-Resistant Bacteria. Antibiotics, 2022, 11, 291.	3.7	5
332	Survey of Early Disapearance of BCR/ABL Fusion Transcript after Allogeneic or Autologous Stem Cell Transplantation for Chronic Myelogenous Leukemia. Leukemia and Lymphoma, 2001, 42, 945-952.	1.3	4
333	Laromustine (cloretazine). Expert Opinion on Pharmacotherapy, 2010, 11, 657-667.	1.8	4
334	Preferences of Older Adults with Cancer for Involvement in Decisionâ€Making about Research Participation. Journal of the American Geriatrics Society, 2014, 62, 1191-1193.	2.6	4
335	The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100â€‰mg/m2intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia. Leukemia and Lymphoma, 2016, 57, 2315-2320.	1.3	4
336	Interim results from a phase 1 first-in-human study of flotetuzumab, a CD123 x CD3 bispecific DART molecule, in AML/MDS. Annals of Oncology, 2017, 28, v355.	1.2	4
337	Mutation patterns in essential thrombocythemia, polycythemia vera and secondary myelofibrosis. Leukemia and Lymphoma, 2019, 60, 1289-1293.	1.3	4
338	Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype. Cancers, 2020, 12, 88.	3.7	4
339	Gains of EPOR and ERG genes in adult erythroleukaemia. British Journal of Haematology, 2020, 189, e174-e177.	2.5	4
340	Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediateâ€risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006â€intermediateâ€risk trial. European Journal of Haematology, 2021, 107, 111-121.	2.2	4
341	Herpesviridae in critically ill hematology patients: HHV-6 is associated with worse clinical outcome. Journal of Critical Care, 2021, 66, 138-145.	2.2	4
342	316â€…EVICTION Study: Preliminary results in solid tumor patients with ICT01, a first-in-class, gamma9 delta2 T cell activating antibody targeting butyrophilin-3A. , 2020, , .		4

#	Article	IF	Citations
343	Allogeneic Hematopoietic Stem Cell Transplantation Improves Outcome of Elderly Patients with Acute Myeloid Leukemia in First Complete Remission: A Time-Dependent and Multistate Analysis from the French Innovative Leukemia Organization. Blood, 2018, 132, 209-209.	1.4	4
344	Sensitive Monitoring of BCR-ABL1 Kinase Domain Mutations By Next Generation Sequencing for Optimizing Clinical Decisions in Philadelphia-Positive Acute Lymphoblastic Leukemia in the Graaph-2014 Trial. Blood, 2019, 134, 1295-1295.	1.4	4
345	Improvement in Cytokine Release Syndrome Management for the Treatment of AML Patients with Flotetuzumab, a CD123 x CD3 Bispecific DartÂ® Molecule for T-Cell Redirected Therapy. Blood, 2019, 134, 5144-5144.	1.4	4
346	Treatment of High Risk MDS and AML Post-MDS with Azacytidine (AZA): Preliminary Results of the French ATU Program.. Blood, 2006, 108, 2664-2664.	1.4	4
347	Phase II Study of VNP40101M (CloretazineÂ®) in Elderly Patients with De Novo Poor Risk Acute Myelogenous Leukemia (AML).. Blood, 2007, 110, 917-917.	1.4	4
348	Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) in AML and Higher Risk MDS with Del 5q. Interim Results of a Phase I/II Study.. Blood, 2009, 114, 1049-1049.	1.4	4
349	Natural Killer Cells Recovery After Consolidation Chemotherapy in Elderly Patients with Acute Myeloid Leukemia (AML). Blood, 2011, 118, 2189-2189.	1.4	4
350	Clofarabine Combinations in Adults with Refractory/Relapsed Acute Lymphoblastic Leukemia (ALL): A GRAALL Report. Blood, 2011, 118, 2586-2586.	1.4	4
351	Impact of High Body Surface Area on AML Outcome in Younger Patients: A Goelams Study. Blood, 2014, 124, 973-973.	1.4	4
352	Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist. Blood, 2016, 128, 2843-2843.	1.4	4
353	Is Azacitidine (AZA) Really Effective in High Risk MDS Patients with Chromosome 7 Abnormalities (Abn) Tj ETQq1 1 0.784314 rgBT /O	1.4	4
354	Efficacy and Safety of Micafungin for Prophylaxis of Invasive Fungal Infections in Patients Undergoing Haplo-Identical Hematopoietic Stem Cell Transplant. Blood, 2012, 120, 4505-4505.	1.4	4
355	Anti-BTN3A 20.1 Agonist Monoclonal Antibody Enhances Autologous Vî³9Vî´2 T Cells Cytotoxicity Against Primary Acute Myeloid Blasts. Blood, 2019, 134, 5153-5153.	1.4	4
356	Blurring lines between treatment intensity and patient fitness in elderly people with AML. Lancet Haematology,the, 2018, 5, e383-e384.	4.6	3
357	Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial). Haematologica, 2018, 103, e519-e521.	3.5	3
358	Prognostic value of monocyte subset distribution in chronic myelomonocytic leukemia: results of a multicenter study. Leukemia, 2021, 35, 893-896.	7.2	3
359	Inflammatory myopathies associated with myelodysplastic syndromes: A French multicenter case control study and literature review. Seminars in Arthritis and Rheumatism, 2021, 51, 845-852.	3.4	3
360	The Management of a Comprehensive Cancer Center during the First Six Months of the COVID-19 Pandemic in the South of France: Lessons from the Paoli-Calmettes Instituteâ€™s Experience. Clinical Hematology International, 2021, 3, 119.	1.7	3

#	Article	IF	Citations
361	Addition of the SMO Inhibitor Sonidegib to Azacitidine in Patients with Higher Risk Myelodysplastic Syndrome (MDS) Who Failed to Respond or Lost Response to AZA Alone: Results of a Phase 1-2 Add-on Study By the GFM. Blood, 2018, 132, 4368-4368.	1.4	3
362	Treatment of Myelodysplastic Syndromes with del 5q before the Lenalidomide Era: The GFM Experience.. Blood, 2006, 108, 2678-2678.	1.4	3
363	Maintenance Therapy by GlivecÂ® and PegasysÂ® in Patients with Philadelphia Positive Acute Lymphocytic Leukemia Not Eligible for Hematopoietic Stem Cell Transplantation.. Blood, 2007, 110, 2812-2812.	1.4	3
364	Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience. Blood, 2012, 120, 422-422.	1.4	3
365	Is Arsenic Trioxide (ATO) Required in the Treatment of Standard Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL 2006) By the French Belgian Swiss APL Group. Blood, 2015, 126, 451-451.	1.4	3
366	Outcome of Patients Treated for Myelodysplastic Syndromes after Failure of Lenalidomide Therapy. Blood, 2015, 126, 95-95.	1.4	3
367	GRASPALL 2005.01 Clinical Study: L-Asparaginase Loaded into Red Blood Cells Is Effective at Depleting Serum Asparagine in Children and Adults with Relapsed Acute Lymphoblastic Leukaemia (ALL). Blood, 2008, 112, 306-306.	1.4	3
368	Positive selection of CD34+ peripheral blood progenitor cells in patients with low-grade lymphoid malignancies and bone marrow involment. Hematology and Cell Therapy, 1999, 41, 5-11.	0.7	2
369	Allogeneic hematopoietic SCT and mechanical heart valve: feasibility of reduced toxicity myeloablative conditioning. Bone Marrow Transplantation, 2010, 45, 1574-1575.	2.4	2
370	Alternative Effective and Safe Induction Regimens for Newly Diagnosed Acute Myeloid Leukemia in Patients With Cardiac Contraindication to Anthracyclines. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e76-e81.	0.4	2
371	Conventional chemotherapy for acute myeloid leukemia in older adults: Impact on nutritional, cognitive, and functional status. European Journal of Haematology, 2021, 106, 859-867.	2.2	2
372	Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Severe Thrombocytopenia: Final Results of a Multicenter Phase II Study. Blood, 2020, 136, 15-16.	1.4	2
373	Gentuzumab-Ozogamicin (GO) Plus Idarubicin (I) and Cytarabine (C) as Induction Treatment for Elderly Patients with Poor-Risk Cytogenetics Acute Myeloid Leukemia (AML).. Blood, 2007, 110, 1839-1839.	1.4	2
374	Decision Criteria for the Futility of Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML).. Blood, 2007, 110, 2861-2861.	1.4	2
375	High Relapse Rate of Acute Myeloid Leukemia with Translocation (8;21) or Inversion (16) in Elderly Patients Treated with Conventional Chemotherapy.. Blood, 2007, 110, 4365-4365.	1.4	2
376	Impact of ATRA Duration during the Induction Treatment of Newly Diagnosed APL. Blood, 2008, 112, 139-139.	1.4	2
377	Risk of AML Evolution In Lower Risk MDS with Del 5q Treated with or without Lenalidomide. A Report by the Groupe Francophone Des Myelodysplasies (GFM). Blood, 2010, 116, 976-976.	1.4	2
378	Lenalidomide (LEN) Combined To Intensive Chemotherapy (IC) In AML and Higher Risk MDS With Del 5q. Results Of a Phase I/II Study Of The Groupe Francophone Des Myelodysplasies (GFM). Blood, 2013, 122, 620-620.	1.4	2

#	Article	IF	Citations
379	The Role of Donor CMV Serostatus on Outcome after T-Cell Replete Haplo-SCT and Post-Transplant Cyclophosphamide: A Cohort Analysis on 207 Consecutive Adult Patients. Blood, 2015, 126, 4401-4401.	1.4	2
380	Adaptive design of VALOR, a phase III trial of vosaroxin or placebo in combination with cytarabine for patients with first relapsed or refractory acute myeloid leukemia.. Journal of Clinical Oncology, 2011, 29, TPS201-TPS201.	1.6	2
381	Outcome of Treatment after First Relapse in Adults Patients with Acute Lymphoblastic Leukemia (ALL) Initially Treated by the LALA-94 Trial.. Blood, 2006, 108, 1876-1876.	1.4	2
382	A Phase I-II Study of Vorinostat and Low Dose Cytarabine for Patients Treated for High Risk Myelodysplastic with Azacytidine Failure: The GFM-VOR2007 Study. Blood, 2010, 116, 4003-4003.	1.4	2
383	A Phase I-II Study Of The Efficacy and Safety Of Lenalidomide (LEN) Combined To Azacitidine (AZA) In Higher Risk MDS and AML With Del 5q â€“ A Study By The Groupe Francophone Des Myelodysplasies (GFM). Blood, 2013, 122, 2750-2750.	1.4	2
384	Therapy Related Myeloid Neoplasm Post PARP Inhibitors: Potential Clonal Selection.. Blood, 2020, 136, 14-15.	1.4	2
385	A prospective, observational study describing the haematological response in patients undergoing chemotherapy treated by tri-weekly darbepoetin alfa for anaemia. Current Medical Research and Opinion, 2010, 26, 2653-2660.	1.9	1
386	5-azacitidine in the treatment of myelodysplastic syndrome and acute myeloid leukemia. International Journal of Hematologic Oncology, 2013, 2, 419-428.	1.6	1
387	Reduced-intensity conditioning regimen with in vivo T-cell depletion for patients with haematological malignancies: results using unrelated and sibling donors. Bone Marrow Transplantation, 2014, 49, 1246-1247.	2.4	1
388	Comparison of Haploidentical T-Replete HSCT Followed with Post-Transplant High Dose Cyclophosphamide (PT-HDCy) with Matched Related (MRD) or Unrelated (UD) HSCT in Patients in or after the 6TH Decade. Biology of Blood and Marrow Transplantation, 2015, 21, S273-S274.	2.0	1
389	Awareness of acute myeloid leukaemia risk induced by diagnosis of a myelodysplastic syndrome. Leukemia Research, 2016, 46, 79-84.	0.8	1
390	JAM-C Expression as a Biomarker to Predict Outcome of Patients with Acute Myeloid Leukemiaâ€”Response. Cancer Research, 2018, 78, 6342-6343.	0.9	1
391	Abstract CT113: A phase III, multicenter, randomized study evaluating the efficacy and safety and efficacy of erythrocyte encapsulated l-asparaginase (Ery001) versus native l-asparaginase (L-asp) in combination with COOPRALL regimen in patients with first relapse of acut. Cancer Research, 2015, 75, CT113-CT113.	0.9	1
392	Number of Mutations and Type of Prior Myeloproliferative Neoplasm Are Prognostic Factors in Acute Myeloid Leukemia Post Myeloproliferative Neoplasms. Blood, 2018, 132, 2806-2806.	1.4	1
393	Evaluation of a Standardized Geriatric Assessment at Diagnosis in a Prospective Cohort of Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2018, 132, 2671-2671.	1.4	1
394	Integrating ELN Criteria and a 'Knowledge Bank' Approach to Guide Allogeneic Stem Cell Transplantation (SCT) Indication in Younger Adults with Acute Myeloid Leukemia (AML): An Acute Leukemia French Association Study. Blood, 2019, 134, 1423-1423.	1.4	1
395	Acute Myeloid Leukemia and Antifungal Prophylaxis Era: Compliance of AML Centers, Invasive Fungal Infection (IFI) Classification, IFI Incidence and AML Outcomes from ALFA 2007- 02 Study. Blood, 2019, 134, 2618-2618.	1.4	1
396	Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia (ALL) at Diagnosis and/or at First Relapse: Results from the GET-LALA Group.. Blood, 2007, 110, 4326-4326.	1.4	1

#	Article	IF	Citations
397	Impact of CRi on the Outcome of Elderly Patients with Acute Myeloid Leukemia.. Blood, 2007, 110, 4384-4384.	1.4	1
398	Should Immunosuppressive Therapy (IST) Be Used More Often In Lower Risk MDS?. Blood, 2010, 116, 1868-1868.	1.4	1
399	Impact of the Provisional Revised-IPSS (R-IPSS) in 265 MDS Patients Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience. Blood, 2011, 118, 972-972.	1.4	1
400	Early Deaths (ED) in Acute Promyelocytic Leukemia (APL) in France: A Retrospective Multicenter Study in 355 Patients (pts). Blood, 2012, 120, 890-890.	1.4	1
401	Azacitidine Treatment For Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia Harboring Chromosome 3q Abnormalities. Blood, 2013, 122, 1512-1512.	1.4	1
402	Impact Of Anthracycline Dose Intensification On Minimal Residual Disease and Outcome Of Core Binding Factors Acute Myeloid Leukemias. Blood, 2013, 122, 2681-2681.	1.4	1
403	Micafungin Versus Fluconazole Or Itraconazole For Prophylaxis Against Invasive Fungal Infections During Neutropenia In Patients Undergoing Haplo-Identical Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 4564-4564.	1.4	1
404	Prognostic Factors Of Response and Survival To Azacitidine (AZA) +/- EPO In RBC Transfusion Dependent (TD) IPSS Low and Int-1 (LR) MDS Resistant To EPO, With Particular Emphasis Of Genetic Lesions: A Study By The GFM. Blood, 2013, 122, 658-658.	1.4	1
405	Preventive Versus Curative Platelet Transfusion Strategies in the Treatment of Acute Myeloid Leukemia Patients: A Comparative Study. Blood, 2014, 124, 4288-4288.	1.4	1
406	A Two-Gene Classifier for Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Report By the GFM. Blood, 2015, 126, 2872-2872.	1.4	1
407	Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs). Blood, 2015, 126, 2880-2880.	1.4	1
408	Evaluation of the Impact of the Presence of Neutralizing L-Asparaginase Antibodies on the Efficacy and Safety of Graspa in Phase 3 Randomized Trial Versus Native L-Asparaginase in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517). Blood, 2015, 126, 3734-3734.	1.4	1
409	Addition of Lomustine (CCNU) to Induction and Post-Remission Chemotherapy for Fit Elderly AML Patients without Unfavorable Cytogenetics: Results of the Lamsa-2007 Goelams Trial. Blood, 2015, 126, 3736-3736.	1.4	1
410	Arsenic Trioxide (ATO) and ATRA with Limited Chemotherapy (CT) in Newly Diagnosed Standard Risk APL in the Elderly. a Report By the French Belgian Swiss APL Group (APL 2006 trial). Blood, 2016, 128, 898-898.	1.4	1
411	Effect of Complete Remission on Survival in Patients With Acute Myelogenous Leukemia Receiving First Salvage Therapy. Blood, 1999, 93, 3149-3150.	1.4	1
412	A randomized phase III study of elacytarabine versus limited investigatorâ€™s choice in patients with refractory acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2011, 29, TPS206-TPS206.	1.6	1
413	A phase II study of elacytarabine plus idarubicin as second course remission-induction therapy in patients with acute myeloid leukemia.. Journal of Clinical Oncology, 2011, 29, TPS207-TPS207.	1.6	1
414	Drug monitoring of ERY001 (erythrocyte encapsulated L-asparaginase) and native L-asparaginase (L-ASP) in combination with COOPRALL regimen in Phase 3 randomized trial in patients with relapsed acute lymphoblastic leukemia.. Journal of Clinical Oncology, 2015, 33, e18036-e18036.	1.6	1

#	Article	IF	Citations
415	Anti-Acute Myeloid Leukemia Activity of Chaetocin, a Novel Epigenetic Drug Inhibitor Inducing Oxidative Stress.. Blood, 2007, 110, 889-889.	1.4	1
416	The Dose of CD34+ Cells Negatively Impacts the Outcome of Patients Treated with Genoidentical Allo SCT Prepared with a Reduced Intensity Conditioning (RIC).. Blood, 2007, 110, 1086-1086.	1.4	1
417	Long-Term Outcome of Anemic Non Del 5q Lower-Risk MDS Refractory to or Relapsing After Erythropoiesis Stimulating Agents (ESAs). Blood, 2010, 116, 442-442.	1.4	1
418	Treatment of Advanced CMML by Azacitidine (AZA) In a Compassionate Program. the GFM Experience In 38 Patients (pts). Blood, 2010, 116, 4023-4023.	1.4	1
419	A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline. Blood, 2012, 120, 46-46.	1.4	1
420	French consensus on myelodysplasic syndrome and chronic myelomonocytic leukemia: diagnostic, classification and treatment 2015 update by the Myelodysplasia French Group. Hematologie, 2015, 21, 28-45.	0.0	1
421	Outcome of Lower Risk Non Del 5q MDS after Failure of Erythropoiesis Stimulating Agents (ESA), and Impact of Post-ESA Treatment on Survival: A Retrospective European Study. Blood, 2015, 126, 1665-1665.	1.4	1
422	A Phase II Add-on Study of Vorinostat (VOR) in Higher Risk Myelodysplastic Syndrome with Failure of Hypomethylating Agents (HMA): The GFM Azavor Study. Blood, 2015, 126, 2900-2900.	1.4	1
423	IDH Mutations Identify a Subgroup of NPM1 Patients with a More Favorable Prognosis. a Retrospective Multicenter Study of the Filo Group. Blood, 2020, 136, 39-40.	1.4	1
424	Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123Ã—CD3 Bispecific DartÂ® Molecule, in Acute Myeloid Leukemia. Blood, 2020, 136, 26-28.	1.4	1
425	IV Busulfan-Based Reduced Intensity Regimen (RIC) Before Allogeneic Stem Cell Transplantation Is Well Tolerate And Effective In Patients With Hematological Diseases. Biology of Blood and Marrow Transplantation, 2010, 16, S295.	2.0	0
426	Subsequent Hematopoietic Stem Cell Transplantation (HSCT) Associated with Longer Survival in Patients with Relapsed/Refractory (R/R) Acute Myelogenous Leukemia (AML) After Clo+Ara-C or Ara-C Alone: A Landmark Analysis from the Classic I Trial. Biology of Blood and Marrow Transplantation, 2012, 18, S211-S212.	2.0	0
427	P-273 Azacitidine treatment for patients with myelodysplastic syndrom and acute myeloid leukemia harboring chromosome 3q abnormalities. Leukemia Research, 2013, 37, S145-S146.	0.8	0
428	An Identical Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic (ALLO) Hematopoietic Stem Cell Transplantation (HSCT) in 222 Patients with Hematologic Malignancies: A Monocenter Experience. Biology of Blood and Marrow Transplantation, 2013, 19, S282.	2.0	0
429	566 GNS396 and analogues are potent new small molecules to target and kill chemotherapy-resistant subpopulation cells in acute myeloid leukemia. European Journal of Cancer, 2014, 50, 183.	2.8	0
430	French consensus on myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia: diagnosis, classification and treatment. Hematologie, 2015, 21, 46-59.	0.0	0
431	213 AZACITIDINE (AZA) IN HIGHER RISK MDS PATIENTS WITH CHROMOSOME 7 ABNORMALITIES (ABN 7): RESULTS OF A RETROSPECTIVE STUDY FROM THE GFM AND GESMD REGISTRIES. Leukemia Research, 2015, 39, S107.	0.8	0
432	Clinical Applications of Epigenetic Drugs. , 2016, , 329-346.		0

#	Article	IF	Citations
433	Epigenetically centered evolution in an example of myeloid malignancy. American Journal of Hematology, 2016, 91, E361-2.	4.1	0
434	T-Replete Haploidentical Allogeneic Transplantation Using Post-Transplantation Cyclophosphamide in Advanced Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2016, 22, S368-S369.	2.0	0
435	Allogeneic Hematopoietic Stem Cell Transplantation for Patients Over 60 Years with Acute Myeloid Leukemia: A Single Center Donor Comparison. Biology of Blood and Marrow Transplantation, 2018, 24, S58-S59.	2.0	0
436	Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma, 2019, 60, 246-249.	1.3	0
437	Topotecan Plus Cytarabine: An Effective and Safe Induction Regimen for Newly Diagnosed Acute Myeloid Leukemia in Patients with Cardiac Contra-Indication to Anthracyclines. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S214.	0.4	0
438	Haplo Allogeneic Hematopoietic Stem Cell Transplantation in Patients of 65 Years or Older: A Monocenter Analysis. Biology of Blood and Marrow Transplantation, 2020, 26, S285.	2.0	0
439	958O Coordinated activation of antitumor responses of g9d2 and CD8 T-cells by targeting BTN3A with ICT01 in patients with solid tumors: EVICTION trial. Annals of Oncology, 2021, 32, S829-S830.	1.2	0
440	Treatment of Newly Diagnosed AML in Unfit Patients. Hematologic Malignancies, 2021, , 215-231.	0.2	0
441	A Second Course of High-Dose Cytarabine before Autologous Stem Cell Transplantation Does Not Improve Outcome of Young Acute Myeloid Leukemia Patients in First Complete Remission: Results of the BGMT 95 Study.. Blood, 2004, 104, 5194-5194.	1.4	0
442	The Role of Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (Allo-SCT) in Patients with Acute Myeloid Leukemia (AML): A Donor vs. No Donor Comparison.. Blood, 2004, 104, 2325-2325.	1.4	0
443	Assessment of Peripheral Blood (PB) Blast Decrease Rate by Multiparameter Flow Cytometry: A New Prognostic Factor in Acute Myeloblastic Leukaemia (AML). A Goelams Study.. Blood, 2006, 108, 1892-1892.	1.4	0
444	Impact of Comorbidities on the Outcome of Elderly Patients with Acute Myeloid Leukemia.. Blood, 2006, 108, 1976-1976.	1.4	0
445	Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) as Salvage Treatment for Relapsing Multiple Myeloma (MM): A â€œDonorâ€•vs. â€œNo Donorâ€•Comparison.. Blood, 2006, 108, 3003-3003.	1.4	0
446	Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Refractory or Relapsed Non-Hodgkinâ€™s Lymphoma (NHL).. Blood, 2006, 108, 5356-5356.	1.4	0
447	Sustained Effect of First Line Sequential Therapy with Intensive Consolidation Chemotherapy and Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) after Reduced Intensity Conditioning (RIC) for Patients with Acute Myeloblastic Leukemia (AML) in First Complete Remission (CR1).. Blood, 2006, 108, 3000-3000.	1.4	0
448	A Double Blind Placebo-Controlled Randomized Phase III Study of High Dose Continuous Infusion Cytosine Arabinoside (araC) with or without CloretazineÂ® in Patients with First Relapse of Acute Myeloid Leukemia (AML).. Blood, 2006, 108, 1970-1970.	1.4	0
449	A Phase I Study with CP-4055 In Patients with Hematologic Malignancies.. Blood, 2007, 110, 901-901.	1.4	0
450	Outcome of Patients with T-Cell Lymphoblastic Leukemia or Lymphoma: The GRAALL Experience.. Blood, 2007, 110, 2818-2818.	1.4	0

#	Article	IF	Citations
451	Graft-Versus Host Disease (GVHD) and Infectious Complications Following Reduced Intensity Conditioning (RIC) Umbilical Cord Blood Transplantation (UCBT) in Adults.. Blood, 2007, 110, 4985-4985.	1.4	0
452	Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Myeloid Leukemia (AML): Long Term Results of a â€œDonorâ€•Versus â€œNo Donorâ€•Comparison.. Blood, 2007, 110, 1090-1090.	1.4	0
453	Results of the AFR07 Prospective Study in De Novo Philadelphia Positive ALL Patients Aged over 55 Years: Efficacy and Safety of a GlivecÂ® Based Induction Followed by Maintenance Therapy with GlivecÂ® and PegasysÂ®.. Blood, 2007, 110, 2816-2816.	1.4	0
454	Improved Outcome by Addition of Lomustine (CCNU) to Idarubicin and Cytarabine in Elderly Patients with De Novo Acute Myeloid Leukemia. A Report from the GOELAMS Group. Blood, 2008, 112, 761-761.	1.4	0
455	Therapy Related APL (tAPL). Prospective Analysis of Etiological Factors In Recent Cases, and Comparison with De Novo Cases. Blood, 2010, 116, 2171-2171.	1.4	0
456	AZA In the Treatment of Therapy Related MDS and AML (tMDS/AML): a Report on 60 Patients by the Groupe Francophone Des Syndromes Myelodysplasiques (GFM). Blood, 2010, 116, 2911-2911.	1.4	0
457	Lenalidomide (LEN) In Lower-Risk Myelodysplastic Syndromes (MDS) with Karyotypes Other Than Deletion 5q and Refractory to Erythropoiesis-Stimulating Agents (ESAs). Blood, 2010, 116, 4002-4002.	1.4	0
458	A Pediatric Treatment of Ph-Negative Acute Lymphoblastic Leukemia (ALL) Is Effective and Safe In Adolescents and Young Adults (AYAs) until 29 Years of Age. Blood, 2010, 116, 2125-2125.	1.4	0
459	Phase 2 Study of Allogeneic Stem Cell Transplantation (ASCT) From Matched Related Donor (MRD) In Patients Older Than 55 Years After Reduced Intensity Conditioning (RIC) Associating Fludarabine, Intravenous Busulfan and Rabbit Thymoglobulin. Blood, 2010, 116, 1320-1320.	1.4	0
460	Correlation Between serum ferritin Level at diagnosis and Survival In Lower Risk, Non-Transfusion Dependent, MDS Patients.A Report by the Groupe Francophone Des Myelodysplasies (GFM). Blood, 2010, 116, 2916-2916.	1.4	0
461	A Prognostic Score for Overall Survival (OS) with Azacitidine (AZA) In Higher Risk MDS Based on 282 Patients (pts), and Validated In 175 Pts From the AZA 001 Trial. Blood, 2010, 116, 3996-3996.	1.4	0
462	Post-Transcriptional Deregulation of MYC Via PTEN Constitutes a Major Alternative Pathway of MYC Activation In T-Cell Acute Lymphoblastic Leukemia. Blood, 2010, 116, 4188-4188.	1.4	0
463	RAD001: A Clinico-Biological Phase I GOELAMS trial of Everolimus Association with High Dose Chemotherapy in Late Relapsing AML Patients Under 65 Years of Age. Blood, 2011, 118, 945-945.	1.4	0
464	Combination of Cytarabine and Topotecan Improves Response Rate for Patients Treated for Acute Myeloid Leukemia with Persistent Disease After Frontline Induction. Blood, 2011, 118, 2605-2605.	1.4	0
465	A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline, and Evaluation of the Impact of the Nucleoside Transporter hENT1 on Response. Blood, 2011, 118, 1533-1533.	1.4	0
466	Gene Mutations and Minimal Residual Disease (MRD) As Predictors of Remission Duration in Adults with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Treated with High-Dose Cytarabine (HDAC) - First Results of the Prospective French Intergroup CBF-2006 Trial. Blood, 2011, 118, 410-410.	1.4	0
467	Fertility in Female Patients After Allogeneic Stem Cell Transplantation Following Reduced-Intensity Conditioning (RIC allo-SCT). Blood, 2011, 118, 3057-3057.	1.4	0
468	Design of N-substituted Amino Caproic Hydroxamic Acid Histone Deacetylase Inhibitors Reveal an Essential Role for Cap Atomic Composition. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 801-806.	1.7	0

#	Article	IF	Citations
469	LOW Tranplant Related Mortality and LOW GRAFT Rejection After Related Haploidentical STEM CELL Transplantation (HAPLO-SCT) Prepared with NON Myeloablative CONDITIONING REGIMEN (NMA) and Posttransplant Cyclophosphamide for Advanced Lymphoid Malignancies.. Blood, 2012, 120, 3031-3031.	1.4	0
470	The Addition of ONE-Day Rest Between LAST ATG Infusion and STEM CELL Infusion DID NOT Affect Gvhd Occurrence After Allogeneic TRANSPLANTATION with Fludarabine-Busulfan-ATG Conditioning.. Blood, 2012, 120, 3029-3029.	1.4	0
471	BCOR Mutations Represent an Independent Factor of Poor Prognosis in Myelodysplastic Syndromes. Blood, 2012, 120, 1697-1697.	1.4	0
472	Post-Transplant Outcome in Patients with Acute Myeloid Leukemia and Myelodysplasic Syndrome Who Received Conditioning Regimen Based On Fludarabin, Busulfan and Anti-Thymoglobulin Prior to Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2012, 120, 2013-2013.	1.4	0
473	Risk Factors of GANCICLOVIRâ€"RELATED Neutropenia After Allogeneic STEM CELL Transplantation: A Retrospective Monocenter Study On 547 Patients. Blood, 2012, 120, 4186-4186.	1.4	0
474	Arsenic Trioxide (ATO) Or ATRA For Consolidation Treatment Of Standard Risk Non Elderly Newly Diagnosed APLâ€" Second Interim Analysis Of a Randomized Trial (APL 2006) By The French Belgian Swiss APL Group. Blood, 2013, 122, 495-495.	1.4	0
475	Use Of Unrelated Donors In Elderly Patients (age >60 years) Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation For Hematologic Malignancies. Blood, 2013, 122, 5544-5544.	1.4	0
476	Reduced Intensity Conditioning Based On Fludarabine, Intravenous Busulfan (2 Days) and Antithymocyte Globulins (2 Days) Results In High Disease Free Survival Without Persisting Gvhd In Patients Transplanted For Hematological Malignancies: Large Single Center Cohort With Long Follow-Up. Blood, 2013, 122, 3364-3364.	1.4	0
477	H3K27me3 Level of the HIST1 Cluster Defines an Epigenetic Marker of Acute Myeloid Leukemia with Prognostic Value. Blood, 2014, 124, 2326-2326.	1.4	0
478	The Comparative Value of Hematopoietic Stem Cell Transplantation and Chemotherapy in Cytogenetically Normal AML Subclassified By NPM1 Mutation Status and FLT3-ITD Allelic Ratio. Blood, 2014, 124, 323-323.	1.4	0
479	Allogeneic HSCT for Patients Aged More Than 55 Years with Myeloid Malignancies: Results of 171 Patients. Blood, 2015, 126, 5525-5525.	1.4	0
480	Prognostic Impact of Response According to International Consortium for MDS/MPN Criteria in CMML Treated with Hypomethylating Agents (HMA). Blood, 2015, 126, 2893-2893.	1.4	0
481	Single Center Experience of Allogenic Hematopoietic Stem Cell Transplantation in 100 Patients with Myelodysplasia: The Impact of Graft-Versus-Host Disease. Blood, 2015, 126, 5537-5537.	1.4	0
482	Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells. Blood, 2015, 126, 2580-2580.	1.4	0
483	Treatment-emergent adverse events (TEAEs) in lenalidomide (LEN)-treated Low-/Int-1-risk myelodysplastic syndromes (MDS) patients (pts) without del(5q) ineligible for or refractory to erythropoiesis-stimulating agents (ESAs).. Journal of Clinical Oncology, 2016, 34, 7061-7061.	1.6	0
484	Evaluation of Salvage Induction Chemotherapy Regimens in Higher Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment Failure. Blood, 2016, 128, 348-348.	1.4	0
485	Is Arsenic Trioxide (ATO) Required in the Treatment of High Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL2006) By the French Belgian Swiss APL Group. Blood, 2016, 128, 895-895.	1.4	0
486	Haploidentical Stem Cell Transplantation for Patients Relapsing after First Allogeneic Transplantation. Blood, 2016, 128, 4618-4618.	1.4	0

#	Article	IF	Citations
487	Abstract 4140: Identification of a selective MKLP2/KIF20A inhibitor with highin-vivoantitumor activity. , 2017, , .		0
488	Characteristics and Outcome of Older Patients with Acute Promyelocytic Leukemia Front-Line Treated with or without Arsenic Trioxide â€" an International Collaborative Study. Blood, 2018, 132, 80-80.	1.4	0
489	Cegal Protocol : Evaluation of the Feasibility of a Chemogenomic Approach to Identify Personalized Therapy for Relapse or Refractory AML Patients. Blood, 2018, 132, 1401-1401.	1.4	0
490	Allogeneic Hematopoietic Stem Cell Transplantation in Patients of 65 Years or Older: A Monocenter Analysis on 252 Patients. Blood, 2019, 134, 4625-4625.	1.4	0
491	Pharmacokinetic-Guided Busulfan Based Myeloablative Versus Fixed Dose Reduced Intensity Conditioning Regimen in Patients Older Than 55 Years Undergoing Allogeneic Stem Cell Transplantation for High Risk Hematological Malignancies. Blood, 2019, 134, 4503-4503.	1.4	0
492	Long Term Analysis of a Monocentric Cohort of Therapy-Related Acute Lymphoblastic Leukemia. Blood, 2020, 136, 23-23.	1.4	0
493	Comparison of a Combination of Vosaroxin (VOS) and Intermediate-Dose Cytarabine (IDAC) with Idac for the Consolidation Therapy of Younger Patients with Favorable- and Intermediate-Risk Acute Myeloid Leukemia (AML) in First Complete Remission (CR): Preliminary Results of a Randomized Phase 2 R4-VOS Study of the French ALFA-Filo AML Intergroup. Blood, 2020, 136, 10-11.	1.4	0
494	Very Long Term Follow up a Phase II Study of Post-Remission Subcutaneous (SC) Azacitidine (AZA) in Patients with AML Post-MDS or Higher-Risk (HR) MDS. Blood, 2020, 136, 1-2.	1.4	0
495	TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia. Blood, 2020, 136, 3-4.	1.4	0